The influence of TNIK gene polymorphisms on risperidone response in a Chinese Han population

References

• 1. Murray CJL, Lopez AD. Measuring global health: motivation and evolution of the Global Burden of Disease Study. Lancet 390(10100), 1460–1464 (2017).
  MedlineGoogle Scholar
• 2. Huhn M, Nikolakopoulou A, Schneider-Thoma J et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 394(10202), 939–951 (2019).
  Medline CASGoogle Scholar
• 3. Pillinger T, Mccutcheon RA, Vano L et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry 7(1), 64–77 (2020).
  MedlineGoogle Scholar
• 4. Mccutcheon RA, Pillinger T, Mizuno Y et al. The efficacy and heterogeneity of antipsychotic response in schizophrenia: a meta-analysis. Mol. Psychiatry 26(4), 1310–1320 (2021).
  Medline CASGoogle Scholar
• 5. Saiz-Rodriguez M, Belmonte C, Roman M et al. Effect of ABCB1 C3435T polymorphism on pharmacokinetics of antipsychotics and antidepressants. Basic Clin. Pharmacol. Toxicol. 123(4), 474–485 (2018).
  Medline CASGoogle Scholar
• 6. Zhou W, Chang W, Yan Y et al. Pharmacogenetics analysis of serotonin receptor gene variants and clinical response to risperidone in Han Chinese schizophrenic patients. Neurosci. Lett. 683, 202–206 (2018).
  Medline CASGoogle Scholar
• 7. Allen JD, Bishop JR. A systematic review of genome-wide association studies of antipsychotic response. Pharmacogenomics 20 (4), 291–306 (2019).
  CASGoogle Scholar
• 8. Sacchetti E, Magri C, Minelli A et al. The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis. Pharmacogenomics J. 17(2), 146–154 (2017).
  Medline CASGoogle Scholar
• 9. Pardiñas AF, Nalmpanti N, Pocklington AJ et al. Pharmacogenomic variants and drug interactions identified through the genetic analysis of clozapine metabolism. Am. J.Gastroenterol. 176 (6) 477–486 (2019).
  Google Scholar
• 10. Zhang J-P, Malhotra AK. Recent progress in pharmacogenomics of antipsychotic drug response. Curr. Psychiatry Rep. 20(4), 24 (2018).
  MedlineGoogle Scholar
• 11. Potkin SG, Turner JA, Guffanti G et al. A genome-wide association study of schizophrenia using brain activation as a quantitative phenotype. Schizophr. Bull. 35(1), 96–108 (2009).
  MedlineGoogle Scholar
• 12. Potkin SG, Macciardi F, Guffanti G et al. Identifying gene regulatory networks in schizophrenia. Neuroimage 53(3), 839–847 (2010).
  Medline CASGoogle Scholar
• 13. Shi J, Levinson DF, Duan J et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 460(7256), 753–757 (2009).
  Medline CASGoogle Scholar
• 14. Martin MV, Rollins B, Sequeira PA et al. Exon expression in lymphoblastoid cell lines from subjects with schizophrenia before and after glucose deprivation. BMC Med. Genomics 2, 62 (2009).
  MedlineGoogle Scholar
• 15. Fu CA, Shen M, Huang BC, Lasaga J, Payan DG, Luo Y. TNIK, a novel member of the germinal center kinase family that activates the c-Jun N-terminal kinase pathway and regulates the cytoskeleton. J. Biol. Chem. 274(43), 30729–30737 (1999).
  Medline CASGoogle Scholar
• 16. Taira K, Umikawa M, Takei K et al. The Traf2- and Nck-interacting kinase as a putative effector of Rap2 to regulate actin cytoskeleton. J. Biol. Chem. 279(47), 49488–49496 (2004).
  Medline CASGoogle Scholar
• 17. Hussain NK, Hsin H, Huganir RL, Sheng M. MINK and TNIK differentially act on Rap2-mediated signal transduction to regulate neuronal structure and AMPA receptor function. J. Neurosci. 30(44), 14786–14794 (2010).
  Medline CASGoogle Scholar
• 18. Kawabe H, Neeb A, Dimova K et al. Regulation of Rap2A by the ubiquitin ligase Nedd4-1 controls neurite development. Neuron 65(3), 358–372 (2010).
  Medline CASGoogle Scholar
• 19. Coba MP, Komiyama NH, Nithianantharajah J et al. TNiK is required for postsynaptic and nuclear signaling pathways and cognitive function. J. Neurosci. 32(40), 13987–13999 (2012).
  Medline CASGoogle Scholar
• 20. Maclaren EJ, Charlesworth P, Coba MP, Grant SG. Knockdown of mental disorder susceptibility genes disrupts neuronal network physiology in vitro. Mol. Cell. Neurosci. 47(2), 93–99 (2011).
  Medline CASGoogle Scholar
• 21. Burette AC, Phend KD, Burette S et al. Organization of TNIK in dendritic spines. J. Comp. Neurol. 523(13), 1913–1924 (2015).
  Medline CASGoogle Scholar
• 22. Anazi S, Shamseldin HE, Alnaqeb D et al. A null mutation in TNIK defines a novel locus for intellectual disability. Hum. Genet. 135(7), 773–778 (2016).
  Medline CASGoogle Scholar
• 23. Lieberman JA, Stroup TS, Mcevoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353(12), 1209–1223 (2005).
  Medline CASGoogle Scholar
• 24. Taipale H, Mehtälä J, Tanskanen A, Tiihonen J. Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia – a nationwide study with 20-year follow-up. Schizophr. Bull. 44(6), 1381–1387 (2018).
  MedlineGoogle Scholar
• 25. Lee ST, Ryu S, Kim SR et al. Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response. J. Clin. Psychopharmacol. 32(4), 441–448 (2012).
  Medline CASGoogle Scholar
• 26. Xing Q, Gao R, Li H et al. Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics 7(7), 987–993 (2006).
  CASGoogle Scholar
• 27. Fijal BA, Kinon BJ, Kapur S et al. Candidate-gene association analysis of response to risperidone in African–American and white patients with schizophrenia. Pharmacogenomics J. 9(5), 311–318 (2009).
  Medline CASGoogle Scholar
• 28. Eum S, Lee AM, Bishop JR. Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations. Dialogues Clin. Neurosci. 18(3), 323–337 (2016).
  MedlineGoogle Scholar
• 29. Ayalew M, Le-Niculescu H, Levey DF et al. Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction. Mol. Psychiatry 17(9), 887–905 (2012).
  Medline CASGoogle Scholar
• 30. Iossifov I, O'roak BJ, Sanders SJ et al. The contribution of de novo coding mutations to autism spectrum disorder. Nature 515(7526), 216–221 (2014).
  Medline CASGoogle Scholar
• 31. Elia J, Glessner JT, Wang K et al. Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder. Nat. Genet. 44(1), 78–84 (2011).
  MedlineGoogle Scholar
• 32. Matigian N, Windus L, Smith H et al. Expression profiling in monozygotic twins discordant for bipolar disorder reveals dysregulation of the WNT signaling pathway. Mol. Psychiatry 12(9), 815–825 (2007).
  Medline CASGoogle Scholar
• 33. Practice guideline for the treatment of patients with bipolar disorder (revision). Am. J. Psychiatry 159(Suppl. 4), 1–50 (2002).
  Google Scholar
• 34. Lehman AF, Lieberman JA, Dixon LB et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am. J. Psychiatry 161(Suppl. 2), 1–56 (2004).
  MedlineGoogle Scholar
• 35. Malone RP, Maislin G, Choudhury MS, Gifford C, Delaney MA. Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. J. Am. Acad. Child Adolesc. Psychiatry 41(2), 140–147 (2002).
  MedlineGoogle Scholar